The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial

David L. Penn, Richard S.E. Keefe, Sonia M. Davis, Piper S. Meyer, Diana O. Perkins, Diane Losardo, Jeffrey A. Lieberman

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

Few pharmacological intervention studies have examined the impact of medication on social cognition, particularly emotion perception. The goal of this randomized, double-blind study is to compare the effects of several second generation antipsychotics and a first generation antipsychotic, perphenazine, on emotion perception in individuals with schizophrenia. Patients were assigned to receive treatment with olanzapine, queitapine fumarate, risperidone, ziprasidone or perphenazine for up to 18 months. Eight hundred and seventy three patients completed an emotion perception test immediately prior to randomization and after 2 months of treatment. We also examined baseline predictors of emotion perception change. Most treatments were associated with a small, non-statistically significant improvement in emotion perception at two months, although they did not differ from one another. Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic.

Original languageEnglish (US)
Pages (from-to)17-23
Number of pages7
JournalSchizophrenia Research
Volume115
Issue number1
DOIs
StatePublished - Nov 2009
Externally publishedYes

Bibliographical note

Funding Information:
Dr. Meyer and Ms. Losardo report no competing interests. Dr. Penn reports having received research funding, consulting fees, advisory board payments, and lecture or educational fees from Bristol-Myers Squib, Eli Lilly, Janssen, Johnson and Johnson, and Repligen. Dr. Keefe reports having received research funding, consulting fees, advisory board payments, and lecture or educational fees from Abbott, AstraZeneca, Acadia, Bristol-Myers Squibb, Cephalon, Cortex, Cyberonics, Dainippon Sumitomo Pharma, Eli Lilly, Gabriel Pharmaceuticals, GlaxoSmithKline, Johnson and Johnson, Lundbeck/Solvay/Wyeth, Memory Pharmaceuticals, Merck, Orexigen, Otsuka, Pfizer, Saegis, Sanofi/Aventis, and Xenoport; he also receives royalties on the Brief Assessment of Cognition (BACS) and MATRICS Battery (BACS Symbol Coding); in addition, he has a personal stake in the CATIE Project as the Director of the Neurocognitive Assessment Unit and MATRICS as a member of the Neurocognitive Committee. Dr. Perkins reports having received research funding from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co., Janssen Pharmaceutica Products, and Pfizer Inc.; and consulting and educational fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals, GlaxoSmithKline, Forest Labs, Pfizer Inc and Shire. Dr. Davis is an employee of Quintiles. Dr. Lieberman reports having received research funding or consulting or educational fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Solvay.

Funding Information:
This article was based on results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project, supported by the National Institute of Mental Health (NO1 MH-90001). Medications for the study were provided by AstraZeneca Pharmaceuticals L.P., Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Janssen Pharmaceutica Products, L.P., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Zenith Goldline Pharmaceuticals, Inc.

Keywords

  • Antipsychotic
  • Emotion perception
  • Pharmacological treatment
  • Schizophrenia
  • Social cognition

Fingerprint Dive into the research topics of 'The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial'. Together they form a unique fingerprint.

Cite this